OCUL

7.58

2.19% -0.17

Dopo l'orario di chiusura: 7.58

Ocular Therapeutix Inc (OCUL)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché OCUL Giù? Forum Previsione

Precedente Chiudi:

$7.75

Aprire:

$7.7

Volume 24 ore:

1.01M

Relative Volume:

0.89

Capitalizzazione di mercato:

$1.23B

Reddito:

$61.10M

Utile/perdita netta:

$-138.36M

Rapporto P/E:

-5.6148

EPS:

-1.35

Flusso di cassa netto:

$-90.59M

1 W Prestazione:

+0.93%

1M Prestazione:

+9.22%

6M Prestazione:

-12.67%

1 anno Prestazione:

-16.70%

Intervallo 1D:

$7.53

$7.82

Intervallo di 1 settimana:

$7.28

$8.04

Portata 52W:

$4.06

$11.78

Ocular Therapeutix Inc Stock (OCUL) Company Profile

Nome

Ocular Therapeutix Inc

Settore

Healthcare (1166)

Industria

Biotechnology (671)

Telefono

781-357-4000

Indirizzo

15 CROSBY DRIVE, BEDFORD, MA

Dipendente

Cinguettio

@OCUTX

Prossima data di guadagno

2025-03-03

Ultimi documenti SEC

OCUL's Discussions on Twitter

Confronta OCUL con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
OCUL Ocular Therapeutix Inc	7.58	1.23B	61.10M	-138.36M	-90.59M	-1.35
VRTX Vertex Pharmaceuticals Inc	492.69	131.41B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	637.36	72.26B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	589.15	35.93B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	268.46	34.75B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	267.39	28.24B	3.81B	-644.79M	-669.77M	-6.24

Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-03-18	Iniziato	RBC Capital Mkts	Outperform
2025-03-11	Iniziato	Needham	Buy
2024-10-16	Iniziato	Scotiabank	Sector Outperform
2024-06-20	Aggiornamento	TD Cowen	Hold → Buy
2024-05-31	Ripresa	Piper Sandler	Overweight
2024-02-09	Iniziato	BofA Securities	Buy
2023-04-21	Iniziato	Robert W. Baird	Outperform
2022-08-10	Ripresa	Berenberg	Buy
2021-08-10	Aggiornamento	H.C. Wainwright	Neutral → Buy
2020-12-28	Downgrade	H.C. Wainwright	Buy → Neutral
2020-12-17	Iniziato	Berenberg	Buy
2020-11-13	Reiterato	Raymond James	Strong Buy
2020-08-10	Reiterato	H.C. Wainwright	Buy
2020-03-03	Aggiornamento	Raymond James	Outperform → Strong Buy
2019-05-21	Downgrade	Cowen	Outperform → Market Perform
2019-05-21	Reiterato	H.C. Wainwright	Buy
2019-05-21	Downgrade	Raymond James	Strong Buy → Outperform
2018-12-03	Reiterato	Cantor Fitzgerald	Overweight
2018-11-15	Iniziato	Raymond James	Strong Buy
2018-09-07	Iniziato	Piper Jaffray	Overweight
2017-10-24	Iniziato	Guggenheim	Buy
2017-07-26	Iniziato	H.C. Wainwright	Buy
2017-07-12	Reiterato	Cantor Fitzgerald	Overweight
2017-06-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2017-02-10	Iniziato	Cantor Fitzgerald	Overweight
2016-11-15	Reiterato	RBC Capital Mkts	Outperform
2016-08-11	Iniziato	JMP Securities	Mkt Outperform
2016-02-17	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2015-10-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2015-08-13	Iniziato	Morgan Stanley	Overweight

Mostra tutto

Ocular Therapeutix Inc Borsa (OCUL) Ultime notizie

Mar 25, 2025

Why Investors Shouldn't Be Surprised By Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) P/S - Simply Wall St

Mar 25, 2025

Mar 21, 2025

Open Angle Glaucoma Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Visiox Pharma, TearClear, VivaVision Biotech, Inc., Abbvie, Ocuphire Pharma, Qlaris Bio, Inc - The Globe and Mail

Mar 21, 2025

Mar 18, 2025

What 4 Analyst Ratings Have To Say About Ocular Therapeutix - Benzinga

Mar 18, 2025

RBC Capital Initiates Coverage of Ocular Therapeutix (OCUL) with Outperform Recommendation - Nasdaq

Mar 18, 2025

Ocular's Axpaxli May Take Wet AMD Market Share, RBC Says -March 18, 2025 at 11:38 am EDT - Marketscreener.com

Mar 18, 2025

RBC Initiates Ocular Therapeutix at Outperform, Speculative Risk With $17 Price Target - Marketscreener.com

Mar 18, 2025

Mar 15, 2025

Ocular rises as Needham issues new Buy on lead candidate - MSN

Mar 15, 2025

Mar 14, 2025

When (OCUL) Moves Investors should Listen - Stock Traders Daily

Mar 14, 2025

Ocular Therapeutix (OCUL) Stock Movement Driven by Analyst Cover - GuruFocus.com

Mar 14, 2025

Why Ocular Therapeutix Was Bumping Higher This Week - Yahoo

Mar 14, 2025

Mar 12, 2025

Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal - AOL

Mar 12, 2025

Ocular Therapeutix (NASDAQ:OCUL) Now Covered by Analysts at Needham & Company LLC - Defense World

Mar 12, 2025

Head-To-Head Review: Corcept Therapeutics (NASDAQ:CORT) vs. Ocular Therapeutix (NASDAQ:OCUL) - Defense World

Mar 12, 2025

Mar 11, 2025

Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside - AOL

Mar 11, 2025

Needham Initiates Ocular Therapeutix at Buy With $15 Price Target -March 11, 2025 at 07:30 am EDT - Marketscreener.com

Mar 11, 2025

This Primoris Services Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga

Mar 11, 2025

Needham Initiates Coverage of Ocular Therapeutix (OCUL) with Buy Recommendation - Nasdaq

Mar 11, 2025

Ocular Therapeutix initiated with a Buy at Needham - TipRanks

Mar 11, 2025

Mar 10, 2025

Ocular Therapeutix at Leerink Conference: Strategic Insights on XPAXLI By Investing.com - Investing.com Canada

Mar 10, 2025

Ocular Therapeutix at Leerink Conference: Strategic Insights on AXPAXLI By Investing.com - Investing.com Australia

Mar 10, 2025

Mar 07, 2025

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Mar 07, 2025

Ocular Therapeutix Awards Stock Options and RSUs to New Employee - StockTitan

Mar 07, 2025

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of “Moderate Buy” from Analysts - Defense World

Mar 07, 2025

HC Wainwright Has Pessimistic Outlook of OCUL Q1 Earnings - Defense World

Mar 07, 2025

Mar 06, 2025

Ocular Therapeutix: Axpaxli’s Dual Trial Strategy And Blockbuster Potential - Seeking Alpha

Mar 06, 2025

Ocular Therapeutix (NASDAQ:OCUL) Earns Buy Rating from HC Wainwright - Defense World

Mar 06, 2025

Mar 05, 2025

Ocular Therapeutix, Inc. to Host Earnings Call - ACCESS Newswire

Mar 05, 2025

Ocular Therapeutix outlines AXPAXLI NDA submission timeline with SOL-1 topline data expected Q1 2026 - MSN

Mar 05, 2025

Truist Financial Corp Acquires Shares of 50,000 Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World

Mar 05, 2025

Traders Purchase High Volume of Call Options on Ocular Therapeutix (NASDAQ:OCUL) - Defense World

Mar 05, 2025

Decoding Ocular Therapeutix Inc (OCUL): A Strategic SWOT Insight - GuruFocus.com

Mar 05, 2025

Mar 04, 2025

Diabetic Retinopathy Pipeline 2025: Mechanism of Action, Route - openPR

Mar 04, 2025

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 04, 2025

Ocular Therapeutix price target lowered to $19 at Citizens JMP, buy on weakness - TipRanks

Mar 04, 2025